Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 10 points (-0.1%) at 13,082 as of Monday, Nov. 5, 2012, 1:34 PM ET. The NYSE advances/declines ratio sits at 1,351 issues advancing vs. 1,574 declining with 129 unchanged. The Drugs industry currently sits up 1.1% versus the S&P 500, which is down 0.1%. A company within the industry that fell today was Pharmacyclics Incorporated ( PCYC), up 10.8%. TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today: 4. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $1.01 (0.6%) to $159.32 on average volume Thus far, 279,823 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 320,900 shares. The stock has ranged in price between $157.11-$159.90 after having opened the day at $157.12 as compared to the previous trading day's close of $158.31. Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $91.7 billion and is part of the health care sector. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are up 37.2% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Novo Nordisk A/S Ratings Report now.